Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Enterprise Value (2016 - 2026)

Ironwood Pharmaceuticals' Enterprise Value history spans 17 years, with the latest figure at -$215.5 million for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 143.29% to -$215.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$215.5 million, a 143.29% decrease, with the full-year FY2025 number at -$215.5 million, down 143.29% from a year prior.
  • Enterprise Value hit -$215.5 million in Q4 2025 for Ironwood Pharmaceuticals, down from -$140.4 million in the prior quarter.
  • Over the last five years, Enterprise Value for IRWD hit a ceiling of -$58.7 million in Q4 2023 and a floor of -$741.6 million in Q1 2023.
  • Historically, Enterprise Value has averaged -$326.3 million across 5 years, with a median of -$196.3 million in 2023.
  • Biggest five-year swings in Enterprise Value: soared 91.07% in 2023 and later tumbled 143.29% in 2025.
  • Tracing IRWD's Enterprise Value over 5 years: stood at -$621.4 million in 2021, then fell by 5.81% to -$657.5 million in 2022, then soared by 91.07% to -$58.7 million in 2023, then tumbled by 50.87% to -$88.6 million in 2024, then plummeted by 143.29% to -$215.5 million in 2025.
  • Business Quant data shows Enterprise Value for IRWD at -$215.5 million in Q4 2025, -$140.4 million in Q3 2025, and -$92.9 million in Q2 2025.